Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell ...

Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...

Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

A newly launched $5 million clinical trial program allows clinical trial sponsors to start trials in as little as 45 days in the Canadian province Ontario. | A newly launched $5 million clinical trial ...

UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...

Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a ...